Characterization of Novel Aryl-Ether, Biaryl, and Fluorene Aspartic Acid and Diaminopropionic Acid Analogs as Potent Inhibitors of the High-Affinity Glutamate Transporter EAAT2
Open Access
- 1 October 2005
- journal article
- Published by Elsevier in Molecular Pharmacology
- Vol. 68 (4) , 974-982
- https://doi.org/10.1124/mol.105.012005
Abstract
In this study, we describe the pharmacological characterization of novel aryl-ether, biaryl, and fluorene aspartic acid and diaminopropionic acid analogs as potent inhibitors of EAAT2, the predominant glutamate transporter in forebrain regions. The rank order of potency determined for the inhibition of human EAAT2 was N4-[4-(2-bromo-4,5-difluorophenoxy)phenyl]-l-asparagine (WAY-213613) (IC50 = 85 ± 5 nM) > N4-(2′-methyl-1,1′-biphenyl-4-yl)-l-asparagine (WAY-213394) (IC50 = 145 ± 22 nM) = N4-[7-(trifluoromethyl)-9H-fluoren-2-yl]-l-asparagine (WAY-212922) (IC50 = 157 ± 11 nM) = 3-{[(4′-chloro-2-methyl-1,1′-biphenyl-4-yl)carbonyl]amino}-l-alanine (WAY-211686) (IC50 = 190 ± 10 nM). WAY-213613 was the most selective of the compounds examined, with IC50 values for inhibition of EAAT1 and EAAT3 of 5 and 3.8 μM, respectively, corresponding to a 59- and 45-fold selectivity toward EAAT2. An identical rank order of potency [WAY-213613 (35 ± 7 nM) > WAY-213394 (92 ± 13 nM) = WAY-212922 (95 ± 8 nM) = WAY-211686 (101 ± 20 nM)] was observed for the inhibition of glutamate uptake in rat cortical synaptosomes, consistent with the predominant contribution of EAAT2 to this activity. Kinetic studies with each of the compounds in synaptosomes revealed a competitive mechanism of inhibition. All compounds were determined to be nonsubstrates by evaluating both the stimulation of currents in EAAT2-injected oocytes and the heteroexchange of d-[3H]aspartate from cortical synaptosomes. WAY-213613 represents the most potent and selective inhibitor of EAAT2 identified to date. Taken in combination with its selectivity over ionotropic and metabotropic glutamate receptors, this compound represents a potential tool for the further elucidation of EAAT2 function.Keywords
This publication has 27 references indexed in Scilit:
- Characterization of Novel L-threo-β-Benzyloxyaspartate Derivatives, Potent Blockers of the Glutamate TransportersMolecular Pharmacology, 2004
- WAY‐855 (3‐amino‐tricyclo[2.2.1.02.6]heptane‐1,3‐dicarboxylic acid): a novel, EAAT2‐preferring, nonsubstrate inhibitor of high‐affinity glutamate uptakeBritish Journal of Pharmacology, 2003
- Effects of threo‐β‐hydroxyaspartate derivatives on excitatory amino acid transporters (EAAT4 and EAAT5)Journal of Neurochemistry, 2001
- Glutamate uptakeProgress in Neurobiology, 2001
- Inducible expression and pharmacology of the human excitatory amino acid transporter 2 subtype of L‐glutamate transporterBritish Journal of Pharmacology, 1999
- New β-Hydroxyaspartate Derivatives Are Competitive Blockers for the Bovine Glutamate/Aspartate TransporterJournal of Biological Chemistry, 1997
- Ionotropic glutamate receptors: new types and new conceptsTrends in Pharmacological Sciences, 1997
- (2S,3S,4R)-2-(Carboxycyclopropyl)glycine, a potent and competitive inhibitor of both glial and neuronal uptake of glutamateNeuropharmacology, 1993
- Cloning and expression of a rat brain L-glutamate transporterNature, 1992
- Conformationally defined neurotransmitter analogs. Selective inhibition of glutamate uptake by one pyrrolidine-2,4-dicarboxylate diastereomerJournal of Medicinal Chemistry, 1991